Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.
Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, Krieg MA, Man Z, Mellström D, Radominski SC, et al. J Bone Miner Res. 2012 Mar; 27(3):694-701.